Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research note released on Friday,Benzinga reports. The firm currently has a $37.00 price target on the stock.

Separately, Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective for the company.

Pharming Group Trading Up 0.3 %

PHAR stock opened at $8.77 on Friday. The firm’s fifty day simple moving average is $8.99 and its two-hundred day simple moving average is $8.59. The stock has a market capitalization of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. Pharming Group has a twelve month low of $6.65 and a twelve month high of $11.80.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $92.70 million during the quarter, compared to analysts’ expectations of $76.67 million. As a group, analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.